Kracov Quoted in Bloomberg BNA on Trump's FDA Nominee
March 16, 2017
Life Sciences and Healthcare Regulatory partner Daniel Kracov was quoted in a recent Bloomberg BNA article, "Trump’s FDA Nominee Spurs Concerns About Drug Approvals, Off-Label Promotion," which evaluates the strengths and weaknesses of FDA Commissioner nominee Scott Gottlieb.
» Read the full article (subscription required).
